Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. (NASDAQ: AGEN) is a pioneering clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. Agenus is steadfast in its mission to develop innovative immunological therapies aimed at leveraging the body's immune system to combat cancer and other diseases. The company’s diverse product pipeline includes immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc., and vaccine adjuvants through its subsidiary SaponiQx Inc. These products are bolstered by in-house capabilities such as current good manufacturing practice (cGMP) manufacturing and a clinical operations platform.
Agenus has developed several key product candidates, including botensilimab (AGEN1811), a next-generation Fc-engineered CTLA-4 antibody, and balstilimab, a PD-1 antibody. They are currently under investigation for their potential to treat various cancers, particularly difficult-to-treat solid tumors.
The company has achieved significant milestones, including the initiation of various clinical trials for botensilimab and balstilimab. Notably, in April 2024, Agenus announced a one-for-twenty reverse stock split of its issued and outstanding common stock to increase its stock price and meet Nasdaq Capital Market listing requirements. This move is part of a strategic plan to enhance future financing and qualify for inclusion in the Russell Indices.
In its ongoing pursuit of innovative cancer treatments, Agenus recently announced Phase 1 trial results demonstrating encouraging survival rates in patients with metastatic colorectal cancer. The Phase 2 data is expected to be submitted to a major medical conference in the latter half of 2024.
Agenus also engages in strategic partnerships to accelerate its development programs. For instance, a recent agreement with Ligand Pharmaceuticals secures a $100 million capital infusion, specifically aimed at supporting the clinical development and launch readiness of the BOT/BAL combination therapy.
The team at Agenus comprises scientists, researchers, biotechnologists, physicians, and business professionals united by the shared goal of achieving breakthroughs in cancer treatment. This collaborative spirit ensures that Agenus remains at the forefront of transformative cancer therapies, aiming to enhance patient outcomes and extend lives.
For more information, visit www.agenusbio.com or follow @agenus_bio on social media.
Agenus (NASDAQ: AGEN) has announced its Annual Shareholders Meeting set for June 8, 2022, at 3:30 p.m. ET, to be held virtually. Shareholders can register from 3:15 p.m. ET via a control number found in proxy materials. The meeting will be accessible in listen-only mode for non-shareholders. Agenus focuses on immuno-oncology, developing therapies that engage the immune system against cancer and infections, utilizing a range of advanced platforms and facilities.
Agenus Inc. (NASDAQ: AGEN) announces botensilimab's late-breaking presentation at the ESMO World Congress on Gastrointestinal Cancer, focusing on treating heavily pretreated MSS colorectal cancer. The company also reveals a strategic plan to cut operating costs by 20% in 2022. Positive clinical responses were highlighted, with botensilimab and balstilimab showing efficacy in difficult-to-treat patients. Agenus aims to accelerate development and prioritize high-potential programs while enhancing operational efficiencies through advanced technologies.
Agenus Inc. (NASDAQ: AGEN) announced significant clinical advancements in its immuno-oncology pipeline. The company is set to initiate Phase 2 trials for botensilimab targeting colorectal, melanoma, and pancreatic cancers, with data updates expected in Q3. AGEN1571 trials will commence following its presentation at AACR, while AGEN2373 is progressing, evidenced by a $5 million milestone payment from Gilead, with potential future payments up to $570 million. Financially, Agenus reported $26 million in revenue for Q1 2022, an increase of $14 million year-over-year, and a net loss of $51 million.
Agenus (NASDAQ: AGEN) will release its Q1 2022 financial results on May 10, 2022, before market opening. The company focuses on immuno-oncology, developing therapies that leverage the immune system against cancer. A conference call and webcast are scheduled for the same day at 8:30 a.m. ET to discuss results and offer a corporate update. The call can be accessed via dial-in numbers provided, and a replay will be available on the company's website. For more information, visit www.agenusbio.com.
Agenus Inc. (Nasdaq: AGEN) announced preclinical data presentation of AGEN1571, a novel anti-ILT2 antibody, at the AACR Annual Meeting on April 8-12, 2022. The data highlight robust adaptive and innate immune responses, showing AGEN1571's superior performance compared to existing clinical-stage competitors. Key findings include a ~10-fold higher binding affinity and complete blockade of ILT2-ligand interactions. The company has cleared its Investigational New Drug (IND) application, paving the way for upcoming clinical trials, further enhancing its immuno-oncology pipeline.
Agenus Inc. (NASDAQ: AGEN) received a $5M clinical milestone payment for AGEN2373, a CD137 agonist, as part of its ongoing Phase 1b study in melanoma patients resistant to prior anti-PD-1 therapy. The combination of AGEN2373 and botensilimab has shown promising preclinical results, boosting tumor control. AGEN2373 is well tolerated, with no liver toxicity reported. Gilead holds an exclusive option to license AGEN2373, while Agenus can opt-in to share development costs, allowing for a potential 50:50 profit split and co-commercialization in the U.S.
Agenus (NASDAQ: AGEN) announced a collaboration with Targovax to develop TG mutant KRAS cancer vaccines combined with Agenus’s QS-21 STIMULON adjuvant. This partnership may lead to an exclusive commercial agreement based on successful clinical trial outcomes. The TG vaccines target mutations in the RAS gene, responsible for approximately 30% of cancers. Targovax has received significant funding to advance the TG program, while QS-21 STIMULON is recognized for its effectiveness in boosting immune responses. Positive clinical results could yield tiered royalties for Agenus.
Agenus Inc. (NASDAQ: AGEN) reported its 2021 financial results, ending with $307 million in cash. The company advanced key clinical programs, notably botensilimab, which has shown promise in treating multiple cold, treatment-resistant cancers. Phase II studies are set to begin for melanoma, MSS-colorectal, and pancreatic cancers, aiming to outperform traditional therapies. Revenue surged to $296 million in 2021, driven by license fees and milestone payments, despite a net loss of $29 million. The firm is strategically positioned for future growth, backed by significant partnerships and proprietary technology.
Agenus (NASDAQ: AGEN) will announce its fourth quarter and full year 2021 financial results before the market opens on March 1, 2022. A conference call will follow at 8:30 a.m. ET, where executives will discuss the financial outcomes and provide a corporate update. Investors are encouraged to participate via dial-in or webcast. The company is focused on advancing immuno-oncology therapies and has a robust pipeline supported by state-of-the-art manufacturing capabilities. Further details can be found on their website.
Agenus (NASDAQ: AGEN), a clinical-stage immuno-oncology company, announced its participation in two investor conferences. The H.C. Wainwright Bioconnect Conference will feature an on-demand presentation starting January 10, 2022. Additionally, they will present at the B. Riley Securities’ 2022 Virtual Oncology Conference on January 27, 2022, at 1:00 PM EST. Investors can access webcasts and replays on the company's website. Agenus focuses on developing therapies that utilize the immune system to combat cancer and has a robust pipeline of treatments.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
What does Agenus Inc. specialize in?
Where is Agenus Inc. headquartered?
What are the key products of Agenus Inc.?
What recent strategic financial move did Agenus make?
What significant agreement did Agenus secure recently?
What are some recent clinical trial achievements of Agenus?
What is the focus of Agenus' product candidates?
Who are part of the Agenus team?
How does Agenus support its product development?
Where can investors find more information about Agenus?
